SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 1002-1006.
  • 2
    Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet. 1993; 341: 1051-1054.
  • 3
    Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood. 1988; 71: 117-122.
  • 4
    Cabanillas F, Hagemeister F, Bodey G. An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982; 60: 693-697.
  • 5
    Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12: 1169-1176.
  • 6
    Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995; 13: 1734-1740.
  • 7
    Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993; 11: 1573-1582.
  • 8
    Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 3776-3785.
  • 9
    Rodriguez-Monge E, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimen. The MD Anderson Cancer Center experience. Hematol Oncol Clin North Am. 1997; 11: 937-947.
  • 10
    Olivieri A, Brunori M, Capelli D, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Hematol. 2004; 72: 10-17.
  • 11
    Vellenga E, van Putten VL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008; 111: 537-543.
  • 12
    Germann N, Brienza S, Rotarski M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non Hodgkin's lymphoma patients. Ann Oncol. 1999; 10: 351-354.
  • 13
    Chau I, Webb A, Cunningham D, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Hematol. 2001; 115: 786-792.
  • 14
    Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998; 9: 1053-1071.
  • 15
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 1244-1253.
  • 16
    SPSS Inc. SPSS for Windows, version 12.0 Chicago, IL: SPSS; 1998.
  • 17
    Philip T, Chauvin F, Armitage J, et al. PARMA international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991; 77: 1587-1592.
  • 18
    Press OW, Livingston R, Mortimer J, et al. Treatment of relapsed non-Hodgkin's lymphoma with dexamethasone, high-dose cytarabine and cisplatin before bone marrow transplantation. J Clin Oncol. 1991; 9: 423-431.
  • 19
    Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation vs. dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomised Italian multicenter study. J Clin Oncol. 1996; 14: 534-542.
  • 20
    Machover D, Del mas-Marsalet B, Misra SC, et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol. 2001; 12: 1439-1443.
  • 21
    El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007; 18: 1363-1368.
  • 22
    Corazzelli G, Russo F, Capobianco G, et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol. 2006; 17( suppl 4): 18-24.
  • 23
    Lopez A, Gutierrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2007; 80: 127-132.